{"id":1069,"date":"2018-01-12T21:00:57","date_gmt":"2018-01-12T21:00:57","guid":{"rendered":"http:\/\/blog.valuengine.com\/?p=1069"},"modified":"2018-01-12T21:00:57","modified_gmt":"2018-01-12T21:00:57","slug":"valuengine-weekly-medical-stocks-jpmorgan-chase-valuation-watch-and-more","status":"publish","type":"post","link":"http:\/\/blog.valuengine.com\/index.php\/valuengine-weekly-medical-stocks-jpmorgan-chase-valuation-watch-and-more\/","title":{"rendered":"ValuEngine Weekly: Medical Stocks, JPMorgan Chase, Valuation Watch, and More"},"content":{"rendered":"

This week, we provide top-five ranked VE data for our Medical Sector stocks. We take a look at our latest data on JPMorgan Chase $JPM and provide a free download link for our stock report on the company. Because overvaluation has crept up again, we now have another Valuation Watch.<\/strong><\/span><\/p>\n

VALUATION WATCH: Overvalued stocks now make up 63.42% of our stocks assigned a valuation and 26.95% of those equities are calculated to be overvalued by 20% or more. Because overvaluation has once again increased above 60%, we have re-insitituted a Valuation Watch. Fifteen sectors are calculated to be overvalued.<\/strong><\/span><\/p>\n

<\/p>\n

ValuEngine Index Overview <\/strong><\/h1>\n\n\n\n\n\n\n\n
Index<\/td>\nWeek Open<\/td>\nFriday PM<\/td>\nChange<\/td>\n% Change<\/td>\nYTD<\/td>\n<\/tr>\n
DJIA<\/strong><\/td>\n25308.4<\/td>\n25759.55<\/td>\n451.15<\/td>\n1.78%<\/td>\n4.21%<\/td>\n<\/tr>\n
NASDAQ<\/strong><\/td>\n7135.38<\/td>\n7251.92<\/td>\n116.54<\/td>\n1.63%<\/td>\n5.05%<\/td>\n<\/tr>\n
RUSSELL 2000<\/strong><\/td>\n1559.8<\/td>\n1590.76<\/td>\n30.96<\/td>\n1.98%<\/td>\n3.60%<\/td>\n<\/tr>\n
S&P 500<\/strong><\/td>\n2742.67<\/td>\n2783.25<\/td>\n40.58<\/td>\n1.48%<\/td>\n4.10%<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n

ValuEngine Market Overview <\/strong><\/h1>\n\n\n\n\n\n\n\n
Summary of VE Stock Universe<\/td>\n<\/tr>\n
Stocks Undervalued <\/strong><\/td>\n36.58%<\/td>\n<\/tr>\n
Stocks Overvalued <\/strong><\/td>\n63.42%<\/td>\n<\/tr>\n
Stocks Undervalued by 20% <\/strong><\/td>\n16.76%<\/td>\n<\/tr>\n
Stocks Overvalued by 20% <\/strong><\/td>\n26.95%<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n

ValuEngine Sector Overview<\/strong><\/h1>\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n
Sector<\/td>\nChange<\/td>\nMTD<\/td>\nYTD<\/td>\nValuation<\/td>\nLast 12-MReturn<\/td>\nP\/E Ratio<\/td>\n<\/tr>\n
Aerospace<\/a><\/td>\n0.74%<\/td>\n3.22%<\/td>\n3.22%<\/td>\n29.25% overvalued<\/td>\n27.98%<\/td>\n23.36<\/td>\n<\/tr>\n
Industrial Products<\/a><\/td>\n1.08%<\/td>\n2.81%<\/td>\n2.81%<\/td>\n16.05% overvalued<\/td>\n27.32%<\/td>\n25.51<\/td>\n<\/tr>\n
Computer and Technology<\/a><\/td>\n0.93%<\/td>\n4.38%<\/td>\n4.75%<\/td>\n15.62% overvalued<\/td>\n35.47%<\/td>\n33.52<\/td>\n<\/tr>\n
Construction<\/a><\/td>\n1.21%<\/td>\n4.01%<\/td>\n4.01%<\/td>\n15.12% overvalued<\/td>\n32.43%<\/td>\n24.37<\/td>\n<\/tr>\n
Multi-Sector Conglomerates<\/a><\/td>\n0.64%<\/td>\n3.17%<\/td>\n3.17%<\/td>\n14.05% overvalued<\/td>\n20.37%<\/td>\n21.92<\/td>\n<\/tr>\n
Transportation<\/a><\/td>\n1.26%<\/td>\n4.37%<\/td>\n4.37%<\/td>\n12.05% overvalued<\/td>\n29.26%<\/td>\n25.22<\/td>\n<\/tr>\n
Consumer Discretionary<\/a><\/td>\n1.05%<\/td>\n2.27%<\/td>\n2.27%<\/td>\n11.23% overvalued<\/td>\n27.86%<\/td>\n26.06<\/td>\n<\/tr>\n
Business Services<\/a><\/td>\n1.07%<\/td>\n2.99%<\/td>\n2.99%<\/td>\n8.93% overvalued<\/td>\n23.72%<\/td>\n26.33<\/td>\n<\/tr>\n
Retail-Wholesale<\/a><\/td>\n1.64%<\/td>\n3.40%<\/td>\n3.40%<\/td>\n8.53% overvalued<\/td>\n18.22%<\/td>\n25.76<\/td>\n<\/tr>\n
Auto-Tires-Trucks<\/a><\/td>\n1.43%<\/td>\n5.97%<\/td>\n5.97%<\/td>\n7.58% overvalued<\/td>\n28.87%<\/td>\n15.88<\/td>\n<\/tr>\n
Finance<\/a><\/td>\n0.60%<\/td>\n2.15%<\/td>\n2.15%<\/td>\n7.18% overvalued<\/td>\n14.28%<\/td>\n19.12<\/td>\n<\/tr>\n
Medical<\/a><\/td>\n1.24%<\/td>\n4.10%<\/td>\n4.10%<\/td>\n6.80% overvalued<\/td>\n46.32%<\/td>\n29.08<\/td>\n<\/tr>\n
Consumer Staples<\/a><\/td>\n0.17%<\/td>\n0.54%<\/td>\n0.54%<\/td>\n5.11% overvalued<\/td>\n19.21%<\/td>\n26.68<\/td>\n<\/tr>\n
Basic Materials<\/a><\/td>\n1.22%<\/td>\n4.82%<\/td>\n4.80%<\/td>\n4.22% overvalued<\/td>\n25.47%<\/td>\n25.93<\/td>\n<\/tr>\n
Utilities<\/a><\/td>\n0.31%<\/td>\n-0.20%<\/td>\n-0.20%<\/td>\n3.29% overvalued<\/td>\n10.13%<\/td>\n22.21<\/td>\n<\/tr>\n
Oils-Energy<\/a><\/td>\n1.97%<\/td>\n7.72%<\/td>\n7.72%<\/td>\n4.44% undervalued<\/td>\n4.81%<\/td>\n29.60<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n

\nSector Talk–Medical <\/strong><\/h1>\n

Below, we present the latest data on Medical stocks from our Professional Stock Analysis Service<\/a>. <\/strong>Top- five lists are provided for each category.\u00a0 We applied some basic liquidity criteria–share price greater than $3 and average daily volume in excess of 100k shares.<\/p>\n

Top-Five Medical Stocks–Short-Term Forecast Returns<\/strong><\/p>\n\n\n\n\n\n\n\n\n
Ticker<\/strong><\/td>\nName<\/strong><\/td>\nMkt Price<\/strong><\/td>\nValuation (%)<\/strong><\/td>\nLast 12-M Return<\/strong> (%)<\/strong><\/td>\n<\/tr>\n
TEVA<\/td>\nTEVA PHARM ADR<\/td>\n21.74<\/td>\n6.16%<\/td>\n-36.58%<\/td>\n<\/tr>\n
FWP<\/td>\nFORWARD PHARMA<\/td>\n4.34<\/td>\nN\/A<\/td>\nN\/A<\/td>\n<\/tr>\n
UTHR<\/td>\nUTD THERAPEUTIC<\/td>\n142.93<\/td>\n20.76%<\/td>\n0.11%<\/td>\n<\/tr>\n
MNK<\/td>\nMALLINCKRODT PL<\/td>\n22.9<\/td>\n-59.62%<\/td>\n-54.60%<\/td>\n<\/tr>\n
ENDP<\/td>\nENDO INTL PLC<\/td>\n7.92<\/td>\n-71.54%<\/td>\n-43.47%<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n

Top-Five Medical Stocks–Momentum<\/strong><\/p>\n\n\n\n\n\n\n\n\n
Ticker<\/strong><\/td>\nName<\/strong><\/td>\nMkt Price<\/strong><\/td>\nValuation (%)<\/strong><\/td>\nLast 12-M Return<\/strong> (%)<\/strong><\/td>\n<\/tr>\n
RCKT<\/td>\nROCKET PHARMACT<\/td>\n12.36<\/td>\nN\/A<\/td>\n616.52%<\/td>\n<\/tr>\n
XOMA<\/td>\nXOMA CORP<\/td>\n33.27<\/td>\n-15.98%<\/td>\n597.48%<\/td>\n<\/tr>\n
MRNS<\/td>\nMARINUS PHARMA<\/td>\n7.57<\/td>\nN\/A<\/td>\n581.98%<\/td>\n<\/tr>\n
MDGL<\/td>\nMADRIGAL PHARMA<\/td>\n98.84<\/td>\n300.00%<\/td>\n524.38%<\/td>\n<\/tr>\n
ESPR<\/td>\nESPERION THERAP<\/td>\n69.91<\/td>\n262.14%<\/td>\n450.47%<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n

Top-Five Medical Stocks–Composite Score<\/strong><\/p>\n\n\n\n\n\n\n\n\n
Ticker<\/strong><\/td>\nName<\/strong><\/td>\nMkt Price<\/strong><\/td>\nValuation (%)<\/strong><\/td>\nLast 12-M Return<\/strong> (%)<\/strong><\/td>\n<\/tr>\n
VRX<\/td>\nVALEANT PHARMA<\/td>\n23.81<\/td>\n-6.95%<\/td>\n55.32%<\/td>\n<\/tr>\n
MYL<\/td>\nMYLAN NV<\/td>\n46.71<\/td>\n0.38%<\/td>\n25.30%<\/td>\n<\/tr>\n
AZN<\/td>\nASTRAZENECA PLC<\/td>\n35.4<\/td>\n9.77%<\/td>\n25.62%<\/td>\n<\/tr>\n
INVA<\/td>\nINNOVIVA INC<\/td>\n14.53<\/td>\n-28.66%<\/td>\n26.35%<\/td>\n<\/tr>\n
LCI<\/td>\nLANNETT INC<\/td>\n24.85<\/td>\n-24.31%<\/td>\n20.63%<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n

Top-Five Medical Stocks–Most Overvalued<\/strong><\/p>\n\n\n\n\n\n\n\n\n
Ticker<\/strong><\/td>\nName<\/strong><\/td>\nMkt Price<\/strong><\/td>\nValuation (%)<\/strong><\/td>\nLast 12-M Return<\/strong> (%)<\/strong><\/td>\n<\/tr>\n
SAGE<\/td>\nSAGE THERAPEUTC<\/td>\n174.6<\/td>\n300.00%<\/td>\n230.37%<\/td>\n<\/tr>\n
CYH<\/td>\nCOMMNTY HLTH SY<\/td>\n4.97<\/td>\n300.00%<\/td>\nN\/A<\/td>\n<\/tr>\n
VIVE<\/td>\nVIVEVE MEDICAL<\/td>\n4.98<\/td>\n300.00%<\/td>\nN\/A<\/td>\n<\/tr>\n
NKTR<\/td>\nNEKTAR THERAP<\/td>\n69.88<\/td>\n300.00%<\/td>\n433.44%<\/td>\n<\/tr>\n
MDGL<\/td>\nMADRIGAL PHARMA<\/td>\n98.84<\/td>\n300.00%<\/td>\n524.38%<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n

 <\/p>\n

Free Download for Readers<\/strong><\/h1>\n

As a bonus to our Free Weekly Newsletter subscribers,
\nwe are offering a FREE DOWNLOAD of one of our Stock Reports<\/strong><\/em><\/p>\n

JPMorgan Chase & Co. (JPM) is a financial services firm. The Company is engaged in investment banking, financial services for consumers and small businesses, commercial banking, financial transaction processing, asset management and private equity. It offers various investment banking products and services, including advising on corporate strategy and structure, capital-raising in equity and debt markets, risk management, market-making in cash securities and derivative instruments, prime brokerage. It also offers consumer and business, and mortgage banking products and services that include checking and savings accounts, mortgages, home equity and business loans, and investments. JPMorgan Chase & Co. is headquartered in New York.<\/p>\n

VALUENGINE RECOMMENDATION: ValuEngine continues its BUY recommendation on JPMORGAN CHASE for 2018-01-11. Based on the information we have gathered and our resulting research, we feel that JPMORGAN CHASE has the probability to OUTPERFORM average market performance for the next year. The company exhibits ATTRACTIVE Company Size and Sharpe Ratio.<\/p>\n

You can download a free copy of detailed report on JPMorgan Chase & Co. (JPM) from the link below.<\/p>\n

R<\/strong><\/em>ead our Complete Rating and Forecast Report <\/strong><\/em>HERE.<\/strong><\/a><\/p>\n

<\/p>\n\n\n\n\n\n\n\n\n\n\n
ValuEngine Forecast<\/strong><\/td>\n<\/tr>\n
<\/td>\nTarget
\nPrice*<\/th>\n		Expected
\nReturn<\/th>\n<\/tr>\n
1-Month<\/strong><\/td>\n111.38<\/td>\n0.49%<\/td>\n<\/tr>\n
3-Month<\/strong><\/td>\n112.15<\/td>\n1.18%<\/td>\n<\/tr>\n
6-Month<\/strong><\/td>\n114.45<\/td>\n3.25%<\/td>\n<\/tr>\n
1-Year<\/strong><\/td>\n117.37<\/td>\n5.89%<\/td>\n<\/tr>\n
2-Year<\/strong><\/td>\n128.45<\/td>\n15.89%<\/td>\n<\/tr>\n
3-Year<\/strong><\/td>\n135.09<\/td>\n21.88%<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n
Valuation & Rankings<\/strong><\/td>\n<\/tr>\n
Valuation<\/strong><\/td>\n17.42% overvalued<\/td>\nValuation Rank<\/strong>(?<\/a>)<\/td>\n31<\/td>\n<\/tr>\n
1-M Forecast Return<\/strong><\/td>\n0.49%<\/td>\n1-M Forecast Return Rank<\/strong><\/td>\n83<\/td>\n<\/tr>\n
12-M Return<\/strong><\/td>\n27.29%<\/td>\nMomentum Rank<\/strong>(?<\/a>)<\/td>\n71<\/td>\n<\/tr>\n
Sharpe Ratio<\/strong><\/td>\n0.92<\/td>\nSharpe Ratio Rank<\/strong>(?<\/a>)<\/td>\n87<\/td>\n<\/tr>\n
5-Y Avg Annual Return<\/strong><\/td>\n17.78%<\/td>\n5-Y Avg Annual Rtn Rank<\/strong><\/td>\n83<\/td>\n<\/tr>\n
Volatility<\/strong><\/td>\n19.40%<\/td>\nVolatility Rank<\/strong>(?<\/a>)<\/td>\n71<\/td>\n<\/tr>\n
Expected EPS Growth<\/strong><\/td>\n14.74%<\/td>\nEPS Growth Rank<\/strong>(?<\/a>)<\/td>\n44<\/td>\n<\/tr>\n
Market Cap (billions)<\/strong><\/td>\n414.34<\/td>\nSize Rank<\/strong><\/td>\n100<\/td>\n<\/tr>\n
Trailing P\/E Ratio<\/strong><\/td>\n16.02<\/td>\nTrailing P\/E Rank<\/strong>(?<\/a>)<\/td>\n79<\/td>\n<\/tr>\n
Forward P\/E Ratio<\/strong><\/td>\n13.96<\/td>\nForward P\/E Ratio Rank<\/strong><\/td>\n67<\/td>\n<\/tr>\n
PEG Ratio<\/strong><\/td>\n1.09<\/td>\nPEG Ratio Rank<\/strong><\/td>\n41<\/td>\n<\/tr>\n
Price\/Sales<\/strong><\/td>\n3.70<\/td>\nPrice\/Sales Rank<\/strong>(?<\/a>)<\/td>\n32<\/td>\n<\/tr>\n
Market\/Book<\/strong><\/td>\n2.03<\/td>\nMarket\/Book Rank<\/strong>(?<\/a>)<\/td>\n56<\/td>\n<\/tr>\n
Beta<\/strong><\/td>\n1.23<\/td>\nBeta Rank<\/strong><\/td>\n28<\/td>\n<\/tr>\n
Alpha<\/strong><\/td>\n-0.00<\/td>\nAlpha Rank<\/strong><\/td>\n52<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n

<\/p>\n

<\/strong><\/p>\n

ValuEngine.com is an Independent Research Provider (IRP), producing buy\/hold\/sell recommendations, target price, and valuations on over 5,000 US and Canadian equities every trading day.<\/strong><\/span>
\n Contact ValuEngine at (800) 381-5576 or support@valuengine.com \u00a0<\/strong><\/span>
\n Visit www.ValuEngine.com for more information<\/a><\/strong><\/span><\/p>\n

\u00a0<\/strong><\/span><\/h1>\n

ValuEngine Capital Management LLC is a Registered Investment Advisory (RIA) firm that trades client accounts using ValuEngine’s award-winning stock research. <\/strong><\/span>
\n Contact ValuEngine Capital at info@valuenginecapital.com<\/strong><\/span>
\n Visit www.ValuEngineCapital.com for more information<\/a><\/strong><\/span><\/p>\n

 <\/p>\n","protected":false},"excerpt":{"rendered":"

This week, we provide top-five ranked VE data for our Medical Sector stocks. We take a look at our latest data on JPMorgan Chase $JPM and provide a free download link for our stock report on the company. Because overvaluation has crept up again, we now have another Valuation Watch. VALUATION WATCH: Overvalued stocks now … Read more<\/a><\/p>\n","protected":false},"author":4,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":[],"categories":[39],"tags":[347,353,65,66,434,763,11,929,765,59,49,341,62,934,927,930,933,437,937,931,936,9,7,64,928,433,68,67,63,439,935,932],"_links":{"self":[{"href":"http:\/\/blog.valuengine.com\/index.php\/wp-json\/wp\/v2\/posts\/1069"}],"collection":[{"href":"http:\/\/blog.valuengine.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"http:\/\/blog.valuengine.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"http:\/\/blog.valuengine.com\/index.php\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"http:\/\/blog.valuengine.com\/index.php\/wp-json\/wp\/v2\/comments?post=1069"}],"version-history":[{"count":1,"href":"http:\/\/blog.valuengine.com\/index.php\/wp-json\/wp\/v2\/posts\/1069\/revisions"}],"predecessor-version":[{"id":1070,"href":"http:\/\/blog.valuengine.com\/index.php\/wp-json\/wp\/v2\/posts\/1069\/revisions\/1070"}],"wp:attachment":[{"href":"http:\/\/blog.valuengine.com\/index.php\/wp-json\/wp\/v2\/media?parent=1069"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"http:\/\/blog.valuengine.com\/index.php\/wp-json\/wp\/v2\/categories?post=1069"},{"taxonomy":"post_tag","embeddable":true,"href":"http:\/\/blog.valuengine.com\/index.php\/wp-json\/wp\/v2\/tags?post=1069"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}